Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Trial Profile

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Ulixertinib (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors BioMed Valley Discoveries
  • Most Recent Events

    • 19 Sep 2018 Status changed from active, no longer recruiting to completed.
    • 17 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Feb 2019.
    • 17 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top